Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against chagas disease

Keyphrases

• Trypanosoma Cruzi (T. cruzi) 100%
• Chagas Disease 100%
• Macrophage Activation 100%
• Vaccine Effectiveness 100%
• Infected Mice 80%
• Mitochondrial DNA 60%
• Tumor Necrosis Factor-α 60%
• Interleukin-10 40%
• Macrophages 40%
• Interleukin-4 (IL-4) 40%
• Tissue Damage 40%
• Unvaccinated 40%
• Parasite Persistence 40%
• Surface Markers 40%
• Nitrosative 40%
• KDNA 40%
• Macrophage Phenotype 40%
• 18S Ribosomal DNA 40%
• T Cells 20%
• United States 20%
• Inflammatory Cytokines 20%
• Emerging Infectious Diseases 20%
• DNA Prime 20%
• Latin America (LATAM) 20%
• Myocarditis 20%
• Disease Severity 20%
• Clinically Significant 20%
• Serum Levels 20%
• B Cells 20%
• Drug Efficacy 20%
• Anti-inflammatory Cytokines 20%
• Vaccine Therapy 20%
• Effective Treatment 20%
• Peripheral Blood 20%
• CD8+ T Cells 20%
• Inflammatory State 20%
• Parasite Burden 20%
• Drug Therapy 20%
• Cytokine Response 20%
• Inflammatory Cytokine Response 20%
• Protein Boost 20%
• CD16 20%
• Challenge Infection 20%
• Macrophage Necrosis 20%
• Lytic Antibodies 20%
• TcDNA 20%
• Cardiac Infiltration 20%
• Serum Constituents 20%
• CD200 20%
• CD32 20%
• CD206 20%

Immunology and Microbiology

• Vaccine Efficacy 100%
• Macrophage 100%
• Chagas Disease 100%
• Tumor Necrosis Factor Alpha 50%
• Interleukin 4 33%
• Interleukin 10 33%
• Cytokine Response 33%
• Kinetoplast 33%
• Infection 33%
• T Cell 16%
• Proinflammatory Cytokine 16%
• Infectious Disease 16%
• Myocarditis 16%
• B Cell 16%
• Inflammatory Cytokine 16%
• Cytotoxic T-Cell 16%
• Trypanosoma Cruzi 16%
• Parasite Load 16%
• CD16 16%
• Blood Level 16%
• Vaccine Therapy 16%
• CD32 16%
• CD200 16%
• Drug Therapy 16%